- Obesity/Metabolic Disease Dominance: Novo Nordisk, Zealand Pharma, Gubra driving massive investment in GLP-1, amylin, and combination therapies
- Radiopharmaceutical Leadership: Norway's alpha-emitter cluster (Oncoinvent, Thor Medical, ArtBio) building on Algeta/Xofigo legacy; Denmark's Curasight
- Gene/Cell Therapy Scale-Up: FinVector (Finland) and NorthX (Sweden) providing critical CDMO infrastructure; Anocca (Sweden) with Nordic's largest cell therapy GMP facility
- AI/Biologics Integration: Evaxion (AI-immunology), Aiforia partnerships, Orion's AI ecosystem grant
- Biosimilar Maturation: Alvotech's 5+ approved products demonstrating Iceland's manufacturing capability
- CDMO Mega-Investments: FUJIFILM $1.6B Hillerød expansion, AGC €160M Copenhagen expansion creating Europe's largest cell culture CDMO capacity
- Consolidation Wave: Multiple mergers (Zelluna/Ultimovacs, 3PBIOVIAN, Calluna) creating larger, more competitive entities
- Marine Biotech Innovation: Kerecis $1.2B exit validating Nordic marine resource applications in biomedicine
This Nordic Biologics Master Directory 2026 was compiled from SwedenBIO member database, Medicon Valley Alliance, Oslo Cancer Cluster, Finnish Bioindustries (FIB), BioPharmGuy Nordic directories, Lusha databases, company websites, SEC/regulatory filings, ClinicalTrials.gov, Crunchbase/PitchBook funding data, and industry publications including FierceBiotech, Endpoints News, BioCentury, Labiotech.eu, and Nordic Life Science News. Information current as of January 2026.
Prepared for Biologics World Nordics 2026 Conference